Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2024-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2024 年半年度报告" which translates to "2024 Semi-Annual Report." It contains detailed financial data, management discussion and analysis, company business overview, R&D progress, and other comprehensive information typical of an interim or quarterly report. The report period is specified as January 1, 2024 to June 30, 2024, confirming it covers a half-year period. The document is lengthy (15,000 characters) and includes actual financial statements and substantive analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
赛伦生物：关于2024年度“提质增效重回报”行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024年度‘提质增效重回报’行动方案的半年度评估报告" which translates to a "2024 Annual 'Quality Improvement, Efficiency Enhancement, and Return' Action Plan Semi-Annual Evaluation Report." It contains detailed operational and financial performance data for the first half of 2024, including revenue, net profit, R&D investment, dividend distribution, shareholding changes by key management, and progress on fundraising projects. The document is about a half-year period and includes substantive financial data and management commentary on business trends and outlook. It is not a full annual report (10-K) but a mid-year comprehensive report with financial statements and analysis. It is not a short announcement or a certification letter, so it is not RPA or RNS. The content fits the definition of an Interim / Quarterly Report (IR). The document length is under 5,000 characters but contains detailed financial and operational data, so it is a report, not just an announcement. Therefore, the correct classification is IR with high confidence. H1 2024
2024-08-27 Chinese
赛伦生物：关于2024年半年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2024 half-year profit distribution plan of Shanghai Sairen Biotechnology Co., Ltd. It details the dividend per share, total dividend amount, and the decision-making process including board and supervisory committee approvals. The document does not contain full financial statements or comprehensive financial analysis but focuses on the dividend distribution specifics and related corporate governance procedures. It is not a full interim or annual report, nor is it a simple notice of report publication. The content fits the category of Notice of Dividend Amount (DIV), as it announces dividend amounts, payment ratios, and related shareholder information for the half-year period.
2024-08-27 Chinese
赛伦生物：第三届监事会第十六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shanghai SAILUN Biotechnology Co., Ltd. regarding the approval of the 2024 semi-annual report, the special report on the use of raised funds, and the profit distribution plan. It includes voting results and confirms compliance with relevant laws and regulations. The document does not contain the actual semi-annual financial report or detailed financial data but refers to the reports being disclosed on the Shanghai Stock Exchange website. The document length is short (1388 characters) and serves as an official announcement of meeting resolutions and approvals rather than the report itself. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2024-08-27 Chinese
赛伦生物：2024年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024 Half-Year Special Report on the Deposit and Actual Use of Raised Funds" by Shanghai SAILUN Biotechnology Co., Ltd. It details the management, storage, and usage of funds raised through a public offering, including specific figures on amounts raised, used, and remaining as of June 30, 2024. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange regarding the management and use of raised funds. It includes detailed tables on fund usage, bank accounts, and investment projects. The document is a specialized report focusing on the use of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). It is not a full annual or interim financial report, nor is it an announcement of a report publication. It is a substantive report on fundraising and capital usage, fitting the CAP category.
2024-08-27 Chinese
上海市锦天城律师事务所关于上海赛伦生物技术股份有限公司实际控制人之一、董事、总经理及部分高级管理人员增持公司股份的法律意见书
Director's Dealing Classification · 100% confidence The document is a legal opinion letter issued by a law firm regarding the shareholding increase by certain key individuals (actual controller, directors, and senior management) of Shanghai Sailun Biotechnology Co., Ltd. It details the legal compliance of the share increase, the qualifications of the shareholders, the shareholding before and after the increase, and confirms that the increase complies with relevant securities laws and regulations. The document is focused on insider share transactions by company directors and executives, specifically their increase in shareholdings. There is no indication that this is a general regulatory filing, an earnings release, or a report publication announcement. The content matches the definition of Director's Dealing, which reports personal share transactions by company directors and executives (insider trades). The document length is over 5,000 characters and contains substantive details about the share transactions, not just an announcement or summary. Therefore, the appropriate classification is DIRS (Director's Dealing).
2024-08-15 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.